Logan 2020.

Study name	Comprehensive geriatric assessment for frail older people with chronic kidney disease to increase attainment of patient‐identified goals ‐ a cluster randomised controlled trial ‐ The GOAL Trial
Methods	Cluster‐randomised trial
Participants	Setting: Australia Inclusion criteria: Moderate to severe chronic kidney disease (CKD) as determined by the treating nephrologist: Stage 3 = eGFR 30 to 59 mL/min/1.73 m² Stage 4 = eGFR 15 to 29 mL/min/1.73 m² Stage 5/5D = eGFR below 15 mL/min/1.73 m², including patients receiving dialysis Aged ≥ 65 years, or ≥ 55 years if Aboriginal or Torres Strait Islander Frailty Index > 0.25 (FI‐CKD tool) Exclusion criteria: Estimated life expectancy of less than 12 months Unable to provide informed consent and/or participate in the Goal Attainment Scaling process
Interventions	Sites will be randomly allocated to either provide a Comprehensive Geriatric Assessment to participants or usual care. A skilled multi‐disciplinary team will provide specialist co‐ordinated care (known as comprehensive geriatric assessment) and will address medical, social, mental health and physical needs. The control sites will receive usual care.
Outcomes	Primary outcome: Goal Attainment Scaling at 3 months Secondary outcomes: Goal Attainment Scaling at 6 and 12 months Quality of life using EQ‐5D‐5L (time frame: 3, 6 and 12 months) Frailty status (time frame: 3, 6 and 12 months). Frailty will be assessed using the Frailty Index CKD Mortality during the 12 months follow‐up Duration of hospital admissions during the 12 months follow‐up Number of hospital admissions during the 12 months follow‐up Number of residential aged care facility admissions at 12 months follow‐up Cost‐effectiveness (time frame: 12 months) Other outcome measures: Process evaluation (time frame: 12 months) Qualitative analysis of structured interviews
Starting date	15 March 2021
Contact information	Laura Robison +61427911414. Email: goal@uq.edu.au
Notes	Trial ID: NCT04538157